As an EGFR- and MET-targeting therapy, amivantamab is associated with various AEs, including skin reactions, peripheral edema, hypoalbuminemia, IRRs, gastrointestinal AEs, and stomatitis. The gene discussed is EGFR; the disease is Hypoalbuminemia.